Numerous studies have consistently identified HER2 overexpression across diverse cancer types including breast, colorectal, ovarian, pancreatic, prostate, bladder, lung, gastric, and gastroesophageal cancers (Yan et al., 2015). Here, ERBB2 is linked to cancer.